Intelligent Beauty Participates In ERSP Forum
New York, NY – January 16, 2009 – The Electronic Retailing Self-Regulation Program (ERSP) has determined that Intelligent Beauty, Inc. has provided a reasonable basis for a general establishment claim, but recommended the marketer modify or discontinue certain claims for the iQ Clear Remedy Acne System.
The marketer’s advertising came to ERSP’s attention pursuant to its ongoing direct response advertising monitoring activities.
ERSP, the electronic direct-response industry’s self-regulatory forum, is administered by the Council of Better Business Bureaus (CBBB) with policy oversight by the National Advertising Review Council (NARC).
ERSP’s inquiry focused on claims included in both online advertising and the product Website. Claims at issue in the ERSP inquiry included:
- “Treats, heals and controls even the toughest acne”
- “97% of users saw no new breakouts!”
- “91%reported clear skin with no active acne”
- “87% saw results in just 3 days”
- “2X’s the acne-clearing power of Proactive”
- “Clearer skin in just 3 days!”
- “Clinically Tested and Proven to Work”
- “Clinically proven to heal the acne you have and prevent new breakouts
- “Clear Remedy outperformed Proactiv in a clinical test. Clear Remedy cleared up acne by 90%. Proactiv only cleared 40%.”
ERSP determined that the marketer’s clinical test provided a reasonable basis for the monadic claim that iQ Clear Remedy is “Clinically Tested and Proven To Work.”
Further, in the course of ERSP’s review, the marketer voluntarily agreed to discontinue the claims discontinued the claims “97% of users saw no new breakouts!”, “91% reported clear skin with no active acne”, “87% saw results in just 3 days”, “2X’s the acne-cleaning power of ProActiv”, as well as the before and after depictions presented online on various websites which purported to represent the results of product use after three days. The marketer agreed also to modify the claim “treats, heals and controls even the toughest acne.”
ERSP determined that an unqualified claim that iQ Clear Remedy provides “Clearer skin in just 3 days!” was not supported by the evidence in the record and recommended that the marketer either modify or discontinue this claim.
ERSP determined that the marketer’s clinical test provided a reasonable basis for the non-comparative claim that iQ Clear Remedy is “Clinically Tested and Proven To Work” but did not provide adequate evidence to support the claim that the iQ Clear Remedy is “Clinically proven to… prevent new breakouts.”
Finally, ERSP determined that the marketer’s testing data did not reliably support the comparative claims disseminated in the advertising.
The company, in its advertiser’s statement said “Although we respectfully disagree with ERSP’s conclusions regarding certain comparative claims, Intelligent Beauty will follow ESRP’s recommendations and modify or discontinue its claims accordingly. Intelligent Beauty is pleased to have participated in ERSP’s self-regulatory process.”
Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.
Latest Decisions
National Advertising Division Finds Realtor.com “#1 Site Real Estate Professionals Trust” Claim Supported
New York, NY – November 8, 2024 – In a challenge brought by competitor CoStar Group, the National Advertising Division determined that Move provided a reasonable basis for its claim that Realtor.com is the “#1 site real estate professionals trust.
National Advertising Division Recommends Verizon Discontinue or Modify Certain Claims for Satellite-Supported Texting Services
New York, NY – November 7, 2024 – In a Fast-Track SWIFT challenge brought by T-Mobile, the National Advertising Division recommended that Verizon either discontinue certain claims about satellite-supported texting services in remote locations or modify them to disclose the necessary conditions for Verizon customers...
Following National Advertising Division Challenge, PetIQ Voluntarily Discontinues Certain Claims for NextStar Flea & Tick Topical
New York, NY – November 6, 2024 – Following a National Advertising Division challenge, PetIQ discontinued certain claims for its NextStar Flea & Tick topical flea prevention and treatment product, which appeared on PetIQ’s website, social media, and third-party websites.
National Advertising Division Finds Certain Safety Claims for Drunk Elephant Skincare Products Supported; Recommends Modification of Influencer Posts
New York, NY – November 4, 2024 – The National Advertising Division determined certain Drunk Elephant social media claims regarding skincare products being “safe for kids and tweens to use” were supported, but determined that two TikTok video influencer disclosures for Drunk Elephant's B-Goldi...